April 7 (Reuters) - NervGen Pharma Corp NGEN.O:
NERVGEN PHARMA ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING AND FDA ALIGNMENT ON RESTORE, A PHASE 3 REGISTRATIONAL STUDY OF NVG-291 FOR CHRONIC TETRAPLEGIA
NERVGEN PHARMA CORP - RESTORE STUDY INITIATION ON-TRACK FOR MID-2026
NERVGEN PHARMA CORP - TO CONCLUDE ENROLLMENT IN PHASE 1B/2A CONNECT SCI SUBACUTE TETRAPLEGIA AND UNBLIND DATA